Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lowe`s Companies Inc (LOW) vs Twist Bioscience Corp (TWST) Price & Performance

Lowe`s Companies IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Lowe`s Companies Inc vs Twist Bioscience Corp — how do they compare? Lowe`s Companies Inc trades at $220.63 (market cap $122.73B), while Twist Bioscience Corp trades at $123.01 (market cap $7.82B). The key difference: Lowe`s Companies Inc is far larger — about 15.7× Twist Bioscience Corp's market cap, and Lowe`s Companies Inc pays a 2.28% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

LOWTWST
Market Cap
$122.73B$7.82B
Sector
Consumer CyclicalHealth
52-Week High
$287.39$124.88
52-Week Low
$201.92$24.16
Enterprise Value
$164.48B$7.75B
Dividend Yield
2.28%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lowe`s Companies Inc

Lowe's (LOW) trades at $223.35, up 2.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $257.69. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Fundamentals show solid profitability with a net income margin of 7.51% and a P/E ratio of 18.88, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights mixed sentiment, with some institutional selling but optimism around the Pro business segment.

The outlook for LOW is cautiously optimistic, supported by strong analyst buy ratings (60.79%) and a dividend payout. Key risks include competitive pressures, macroeconomic sensitivity, and high debt levels. The upcoming Q2 earnings report on August 19, 2026, will be critical for validating growth expectations and could drive near-term price movement.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Lowe`s Companies Inc

Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.

Read more on LOW

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST